Benzinga · Aug 17, 2026
Maxim Group Downgrades cbdMD to Hold
Maxim Group analyst Anthony Vendetti downgrades cbdMD (AMEX:YCBD) from Buy to Hold.
AMEX · YCBD
cbdMD, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.51
Up+$0.00 (+0.77%)
Updated Aug 23, 2026, 7:26 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.58M
- P/E ratio
- -1.44
- Dividend yield
- 0.00%
- 52-week range
- $0.47 – $2.56
- Volume
- 149.12K
- Avg. volume
- 3.96M
Price performance
YCBD price history
1M range · 20 trading sessions · Daily adjusted prices
YCBD closed at $0.51 after 20 trading sessions, down 2.13% for the selected period.
- Last close
- $0.51
- Period change
- -2.13%
- Period low
- $0.47
- Period high
- $0.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.4854 | $0.52 | $0.4854 | $0.5089 | 149.12K |
| Aug 20, 2026 | $0.4899 | $0.505 | $0.4801 | $0.505 | 38.17K |
| Aug 19, 2026 | $0.4998 | $0.5099 | $0.485 | $0.49 | 142.39K |
| Aug 18, 2026 | $0.49 | $0.4905 | $0.47 | $0.47 | 42.14K |
| Aug 17, 2026 | $0.50 | $0.50 | $0.469 | $0.475 | 100.66K |
| Aug 14, 2026 | $0.5645 | $0.58 | $0.487 | $0.4958 | 496.99K |
| Aug 13, 2026 | $0.59 | $0.61 | $0.56 | $0.565 | 223.65K |
| Aug 12, 2026 | $0.5845 | $0.62 | $0.5724 | $0.598 | 203.05K |
| Aug 11, 2026 | $0.5664 | $0.59 | $0.551 | $0.585 | 175.85K |
| Aug 10, 2026 | $0.5609 | $0.585 | $0.5344 | $0.566 | 365.52K |
| Aug 7, 2026 | $0.56 | $0.5892 | $0.56 | $0.565 | 105.83K |
| Aug 6, 2026 | $0.57 | $0.5889 | $0.56 | $0.5657 | 81.05K |
| Aug 5, 2026 | $0.57 | $0.59 | $0.57 | $0.59 | 54.74K |
| Aug 4, 2026 | $0.557 | $0.5843 | $0.5401 | $0.558 | 341.88K |
| Aug 3, 2026 | $0.509 | $0.5729 | $0.50 | $0.5695 | 381.3K |
| Jul 31, 2026 | $0.48 | $0.5343 | $0.48 | $0.5069 | 161.61K |
| Jul 30, 2026 | $0.49 | $0.4999 | $0.465 | $0.471 | 268.06K |
| Jul 29, 2026 | $0.51 | $0.51 | $0.4701 | $0.489 | 158.73K |
| Jul 28, 2026 | $0.53 | $0.53 | $0.49 | $0.50 | 176.88K |
| Jul 27, 2026 | $0.5425 | $0.5498 | $0.50 | $0.52 | 171.63K |
Latest YCBD news
The latest Smart Investors Daily articles mentioning YCBD.
Stock researchCompany · Overview
YCBD research
Overview
Company profile and research snapshot.
Company profile
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Maxim Group | Hold | — |
| Aug 20, 2025 | Maxim Group | Buy | — |
| May 22, 2025 | Maxim Group | Buy | — |
| Oct 5, 2023 | Maxim Group | Buy | — |
| Jun 18, 2021 | Cantor Fitzgerald | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 14, 2026
cbdMD Inc (YCBD) (Q3 2026) Earnings Call Highlights: Strategic Pivot and Cost Cuts Aim to ...
cbdMD Inc (YCBD) reports 20% revenue growth driven by wholesale and Oasis brand momentum, while implementing aggressive cost reductions to lower breakeven and navigate a shifting regulatory landscape.
SeekingAlpha · Aug 13, 2026
cbdMD, Inc. (YCBD) Q3 2026 Earnings Call Transcript
Yahoo · Aug 13, 2026
cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026
cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its hemp-derived THC beverage brand Oasis and functional-mushroom brand ATRx Labs, today announced financial results for the third quarter of fiscal year 2026, ended June 30, 2026.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
